1. Field of the Invention
The invention relates to a method for fabricating nanoparticles containing fenofibrate.
2. Description of the Related Art
Nanotechnology is widely used in various fields such as biochemistry, medicine and chemical engineering. Regarding to medicine transfer in the biomedical field, for example, nanonization of medicines can effectively increase the total particle surface area of medicines, thus accelerating absorption rate of medicines and bioavailability. The key point of therapy using medicines is whether the medicines can be essentially (or completely) absorbed, thus particle dimensions and uniformity may directly influence the therapeutic effect.
Present nanonization of medicines may comprise physical and chemical methods. Physical methods include, for example, electrospray, ultrasound, spray drying, superior fluid, and cryogenic technology. For example, U.S. Pat. No. 6,368,620 discloses a process for preparing a nanocrystal or nanoparticle fibrate composition. U.S. Pat. No. 6,682,761 disclose a process for the preparation of small particles containing a poorly water soluble drug. U.S. Pat. No. 6,696,084 discloses a process for the preparation of small particles or microparticles containing fenofibrate and a phospholipid surface stabilizing substance. Most technologies have a common issue i.e. uneven distribution of particle diameters, which can be solved by subsequent filtering, however, manufacturing process complexity, and cost also increases. Accordingly, processes suitable for large-scale production capable of obtaining nanoparticles (such as nanoparticles containing fenofibrate) with uniform diameter are desirable.
One embodiment of the invention discloses a method for fabricating nanoparticles containing fenofibrate, comprising: (a) mixing a hydrophobic substance, an organic solvent and a solubility enhancing additive to form a saturated solution; and (b) spray-drying the saturated solution to form the nanoparticles containing the hydrophobic substance, wherein the solubility enhancing additive comprises a surfactant or an excipient.
Another embodiment of the invention discloses a method for fabricating nanoparticles containing fenofibrate and that the hydrophobic substance comprises fenofibrate.
Another embodiment of the invention discloses a method for fabricating nanoparticles containing fenofibrate and that the solvent comprises an organic solvent.
Another embodiment of the invention discloses a method for fabricating nanoparticles containing fenofibrate and that the organic solvent comprises alcohol.
Another embodiment of the invention discloses a method for fabricating nanoparticles containing fenofibrate and that the additive comprises a surfactant or excipient.
The solubility and of active ingredients (for example, fenofibrate) in solution can be increased by means of utilizing the solubility enhancing additive.
A detailed description is given in the following embodiments with reference to the accompanying drawings.
The present invention can be more fully understood by reading the subsequent detailed description and examples with references made to the accompanying drawings, wherein:
The following description is of the best-contemplated mode of carrying out the invention. This description is made for the purpose of illustrating the general principles of the invention and should not be taken in a limiting sense. The scope of the invention is best determined by reference to the appended claims.
Embodiments of the invention provide methods for fabricating nanoparticles from a supersaturated liquid solution with a substance to be transformed into nanoscale. The liquid solution is preferably composed of a solvent, a solubility enhancing additive, and the substance to be transformed into nanoscale dissolved therein. The solvent, for example, can be alcohol (also ethanol). However, other solvents, or mixtures of solvents, which can dissolve the substance and are miscible with the anti-solvent selected in the nanoparticle formation device are also suitable. An example of a solubility enhancing additive is a surfactant (i.e. Brij 76 (purchased from Sigma-Aldrich, St. Louis, Mo.)); nonetheless, other additives that are able to increase the intrinsic solubility of the substance in the solvent are also included. In addition, substances suitable to be transformed into nanoscale include bioactive material, polymer material, biomaterial, chemical material or mixtures thereof. Note that the substances are active agents in the solvent. Furthermore, the additive is a stabilizer or an excipient.
Nanoparticle fabrication, the process of which a substance to be transformed into nanoparticle, is done via fabrication apparatus and process described later.
The micro droplet sprayer 110, for example, can be an inkjet sprayer including a liquid tank (not shown), a channel (not shown), an actuator (not shown), and orifices (not shown). The actuator drives several orifices to spray the solution, thus micro droplets 112 are generated. The actuator can be a thermal bubble actuator or a piezoelectric actuator. In embodiments of the invention, the solution such as a medicine solution employing alcohol as a solvent is poured into the micro droplet sprayer 110. The drying chamber 115 is used to collect and dry the droplets 112, and it can be a thermal dryer or a hot air generator. The liquid supplier and pressure controller 120 are capable of supplying liquid steadily and controlling the pressure required by micro droplet sprayer 110, thus avoiding the pressure change rendered by the volume change of solution during operation. Driving forces of the pressure controller 120 comprise mechanical forces, atmosphere difference or potential difference. The device (e.g. a controller or a control system) 130 can provide the micro droplet sprayer 110 with various energy pulses or other parameters for spraying liquid. The nitrogen suppliers 140 are provided for keeping oxygen concentration to less than a specific value by steadily providing the system with nitrogen because the system 100 utilizes an organic solvent as solvent of the medicinal solution to be sprayed and is operated under high temperature that may cause an explosion. The inner loop 150 can recycle the nitrogen (the heated nitrogen can be used as hot air) and condense organic solvent for collection. The particle collector 160 and particle filter 170 can prevent particles from escaping into the air.
The liquid supplier and pressure controller 120 inject the medicine solution into the micro droplet sprayer 110. In addition, The micro droplet sprayer 110 is driven by the device (e.g. a controller or a control system) 130 to spray the medicine solution, thus micro droplets 112 are formed in the drying chamber 115. The nitrogen supplier 140 simultaneously injects nitrogen into the drying chamber 115, generating hot air 125 and drying the micro droplets 112 released from the micro droplet sprayer 110. As a result, nanoparticles (i.e. the dried micro droplets 112) are obtained. The nanoparticles then settle to the bottom 117 of drying chamber 115 for collection by the particle collector 160 following the direction of arrow 119. The nanoparticles, remaining in the nitrogen, however, are trapped by the particle filter 170. The used nitrogen is then recycled by means of the inner loop 150 and enters the drying chamber 115 again. In embodiments of the invention, an auxiliary element (not shown) for controlling spray directions of the droplets 112 is provided, thus avoiding turbulence or collision therebetween during operation of micro droplet sprayer 110. In addition, the auxiliary element is arranged in a front end of the micro droplet sprayer and the shape of the auxiliary element is cylindrical or conical.
As shown in
In the following five embodiments, a medicine solution containing fenofibrate is employed in the system 100 shown in
The solubility of fenofibrate (substance) in ethanol was increased from value of 2.5% (w/v) with an excipient such as poly vinyl pyrrolidone (PVP) at substance to excipient ratio of 1:1 to 10% (w/v) with an excipient such as Brij 76 (purchased from Sigma-Aldrich, St. Louis, Mo.) at substance to excipient ratio of 1:1. Precipitation of substance was observed overnight suggesting supersaturation phenomenon.
The solubility of fenofibrate (substance) in ethanol was increased from value of 2.5% (w/v) with an excipient such as poly vinyl pyrrolidone (PVP) at substance to excipient ratio of 1:1 to 10% (w/v) with an excipient such as Brij 76 (purchased from Sigma-Aldrich, St. Louis, Mo.) at substance to excipient ratio of 1:2. As shown in
The solubility of fenofibrate (substance) in ethanol was increased from value of 2.5% (w/v) with an excipient such as poly vinyl pyrrolidone (PVP) at substance to excipient ratio of 1:1 to 10% (w/v) with an excipient such as D-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS), purchased from Eastman Chemical Company, Kingsport, Tenn.) at substance to excipient ratio of 1:1. Precipitation of substance was observed overnight suggesting supersaturation phenomenon.
The solubility of fenofibrate (substance) in ethanol was increased from value of 2.5% (w/v) with an excipient such as poly vinyl pyrrolidone (PVP) at substance to excipient ratio of 1:1 to 10% (w/v) with an excipient such as D-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS), purchased from Eastman Chemical Company, Kingsport, Tenn. at substance to excipient ratio of 1:2. Precipitation of substance was observed overnight suggesting supersaturation phenomenon. As shown in
The solubility of fenofibrate (substance) in ethanol was increased from value of 2.5% (w/v) with an excipient such as poly vinyl pyrrolidone (PVP) at substance to excipient ratio of 1:1 to 10% (w/v) with an excipient such as Solutol HS15 mainly including poly-oxyethylene esters of 12-hydroxystearic acid (manufactured by BASF, Florham Park, N.J.) at substance to excipient ratio of 1:1.
The solubility of fenofibrate (substance) in ethanol was increased from value of 2.5% (w/v) with an excipient such as poly vinyl pyrrolidone (PVP) at substance to excipient ratio of 1:1 to 10% (w/v) with an excipient such as Arlacel 83 mainly including sorbitan sesquioleate (manufactured by Stobec, Quebec, Canada) at substance to excipient ratio of 1:1.
As described, the invention fabricates nanoparticles with uniform diameters by integrating injection printing techniques into subsequent drying and formation processes. In addition, the system is further equipped with the auxiliary element for controlling spray directions of the droplets and particle collector for collecting dried nanoparticles. Compared to the related art, the invention has advantages such as low cost, fine droplets, uniform droplet diameters, and simple apparatus and processes. Specifically, the nanoparticles fabricated by the invention have uniform particle diameters, thus, they can be used to manufacture medicines enhancing absorption and solubility in the blood. The invention aids in improving the therapeutic effect of medicines.
While the invention has been described by way of example and in terms of the preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments. To the contrary, it is intended to cover various modifications and similar arrangements (as would be apparent to those skilled in the art). Therefore, the scope of the appended claims should be accorded the broadest interpretation so as to encompass all such modifications and similar arrangements.
This application is related to a co-pending U.S. application Ser. No. 11/562,958, filed on Nov. 22, 2006, the entire disclosure of which is incorporated herein by reference.